Andrea B Apolo

List of Publications by Citations

64 papers	2,455 citations	23 h-index	49 g-index
72 ext. papers	3,342 ext. citations	6.4 avg, IF	4.85 L-index

#	Paper	IF	Citations
64	Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. *Journal of Clinical Oncology*, **2017**, 35, 2117-2124	2.2	415
63	Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. *Lancet Oncology, The*, **2018**, 19, 51-64	21.7	362
62	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *New England Journal of Medicine*, **2021**, 384, 829-841	59.2	280
61	Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. *Journal of Clinical Oncology*, **2010**, 28, 3973-8	2.2	124
60	Novel tracers and their development for the imaging of metastatic prostate cancer. *Journal of Nuclear Medicine*, **2008**, 49, 2031-41	8.9	109
59	Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. *Journal of Clinical Oncology*, **2013**, 31, 724-30	2.2	76
58	Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. *Journal of Nuclear Medicine*, **2016**, 57, 886-92	8.9	64
57	Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. *Journal of the National Cancer Institute*, **2013**, 105, 499-503	9.7	63
56	The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. *Journal of Nuclear Medicine*, **2012**, 53, 1175-84	8.9	57
55	Repeatability of Quantitative 18F-NaF PET: A Multicenter Study. *Journal of Nuclear Medicine*, **2016**, 57, 1872-1879	8.9	46
54	Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer. *Clinical Cancer Research*, **2019**, 25, 3689-3701	12.9	45
53	A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. *BJU International*, **2015**, 116, 546-55	5.6	45
52	Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies.. *Journal of Clinical Oncology*, **2018**, 36, 515-515	2.2	42
51	Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 637-44	2.8	41
50	Quantitative Assessment of Early [F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone. *Journal of Clinical Oncology*, **2017**, 35, 2829-2837	2.2	39
49	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. *Journal of Clinical Oncology*, **2020**, 38, 3672-3684	2.2	37
48	Advances in medical imaging for the diagnosis and management of common genitourinary cancers. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 473-491	2.8	35

47	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. *Clinical Genitourinary Cancer*, **2017**, 15, 77-85	3.3	33
46	Immunotherapy: a new treatment paradigm in bladder cancer. *Current Opinion in Oncology*, **2017**, 29, 184-195	4.2	33
45	Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. *Lancet Oncology, The*, **2020**, 21, 1099-1109	21.7	31
44	Targeted therapies in urothelial carcinoma. *Current Opinion in Oncology*, **2014**, 26, 305-20	4.2	31
43	Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib. *JAMA Dermatology*, **2015**, 151, 170-7	5.1	26
42	Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. *Urologic Oncology: Seminars and Original Investigations*, **2012**, 30, 772-80	2.8	26
41	Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer. *Journal of Immunology*, **2019**, 202, 3458-3467	5.3	23
40	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. *Bladder Cancer*, **2016**, 2, 165-202	1	22
39	Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma. *Thyroid*, **2014**, 24, 1223-31	6.2	22
38	Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies. *Ocular Immunology and Inflammation*, **2020**, 28, 854-859	2.8	21
37	Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development. *Clinical Genitourinary Cancer*, **2018**, 16, 117-129	3.3	21
36	Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. *Journal of Urology*, **2020**, 204, 1173-1179	2.5	20
35	Imaging muscle-invasive and metastatic urothelial carcinoma. *Current Opinion in Urology*, **2015**, 25, 441-8	2.8	18
34	Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis **2020**, 8,		18
33	Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma. *Clinical Genitourinary Cancer*, **2015**, 13, 410-20	3.3	16
32	New and promising strategies in the management of bladder cancer. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2015**, 105-12	7.1	14
31	Serum Metabolic Profiling Identified a Distinct Metabolic Signature in Bladder Cancer Smokers: A Key Metabolic Enzyme Associated with Patient Survival. *Cancer Epidemiology Biomarkers and Prevention*, **2019**, 28, 770-781	4	14
30	Rapid development of migratory, linear, and serpiginous lesions in association with immunosuppression. *Journal of the American Academy of Dermatology*, **2014**, 70, 1130-4	4.5	12

29	Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder. *Journal of Translational Medicine*, **2014**, 12, 199	8.5	12
28	Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma. *Current Treatment Options in Oncology*, **2018**, 19, 36	5.4	12
27	Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 53-64	2.8	11
26	Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder. *Cancers*, **2014**, 6, 2313-29	6.6	11
25	Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. *Clinical Genitourinary Cancer*, **2018**, 16, 213-218	3.3	10
24	Clinical states model for biomarkers in bladder cancer. *Future Oncology*, **2009**, 5, 977-92	3.6	10
23	Viable tumor volume: Volume of interest within segmented metastatic lesions, a pilot study of proposed computed tomography response criteria for urothelial cancer. *European Journal of Radiology*, **2015**, 84, 1708-14	4.7	9
22	Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naïve (n) or refractory (r) to checkpoint inhibitor (CPI).. *Journal of Clinical Oncology*, **2018**, 36, 4528-4528	2.2	9
21	Radiology Reports With Hyperlinks Improve Target Lesion Selection and Measurement Concordance in Cancer Trials. *American Journal of Roentgenology*, **2017**, 208, W31-W37	5.4	8
20	Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer. *Clinical Cancer Research*, **2021**, 27, 1391-1398	12.9	7
19	ENABLE (Exportable Notation and Bookmark List Engine): an Interface to Manage Tumor Measurement Data from PACS to Cancer Databases. *Journal of Digital Imaging*, **2017**, 30, 275-286	5.3	6
18	Clinical value of FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 787.e17-787.e21	2.8	6
17	Quantification of bone flare on F-NaF PET/CT in metastatic castration-resistant prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2019**, 22, 324-330	6.2	6
16	F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 178-184	8.8	6
15	Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literature. *Clinical Case Reports (discontinued)*, **2020**, 8, 24-32	0.7	5
14	Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. *JAMA Oncology*, **2019**, 5, 1790-1798	13.4	5
13	Efficacy and immune-related adverse event associations in avelumab-treated patients **2020**, 8,		5
12	Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review.. *Cancer Treatment Reviews*, **2021**, 103, 102333	14.4	4

List of Publications

11	Targeting molecular aberrations in urothelial carcinoma: are we almost there?. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2013**, 195-9	7.1	3
10	Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).. *Journal of Clinical Oncology*, **2021**, 39, 4561-4561	2.2	3
9	Targeting Molecular Aberrations in Urothelial Carcinoma: Are We Almost There?. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2013**, 195-199	7.1	2
8	Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder. *PLoS ONE*, **2021**, 16, e0241766	3.7	2
7	Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors.. *Nature Communications*, **2022**, 13, 1487	17.4	2
6	Systemic therapy in bladder preservation. *Urologic Oncology: Seminars and Original Investigations*, **2020**,	2.8	1
5	Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2022**, 1-16	7.1	1
4	Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer. *Clinical Genitourinary Cancer*, **2019**, 17, 306-314	3.3	0
3	MPA software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays.. *Cell Reports Methods*, **2022**, 2, 100136		0
2	CT Evaluation of Lymph Nodes That Merge or Split during the Course of a Clinical Trial: Limitations of RECIST 1.1. *Radiology Imaging Cancer*, **2021**, 3, e200090	1.4	0
1	Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. *Journal of Clinical Oncology*, **2014**, 32, 4172-3	2.2	